Press Releases
Litigator Mark Remus Speaks on Litigation Defense Strategies at Third Annual IP Strategy Summit
May 03, 2017

CHICAGO—Mark H. Remus, a shareholder and patent litigator at intellectual property law firm Brinks Gilson & Lione, will be a panelist for “Defensive Strategy 2.0: Facing a Better-Prepared Plaintiff” at CenterForce’s third annual IP Strategy Summit on May 3, 2017, at the Fairmont Olympic Hotel in Seattle.

Remus and two in-house attorneys will discuss proactive defense strategies for a litigation environment with leaner and better-prepared plaintiffs, including maximizing resources, determining the endgame, anticipating enforcement strategies and formulating a response, and effectively partnering with outside counsel.

Remus is a seasoned trial lawyer who has served as lead counsel on numerous patent infringement litigation matters. He represents clients in jury trials, bench trials, and appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. Remus has extensive experience with pharmaceutical litigation under the Hatch-Waxman Act, as well as experience protecting and defending other technologies. He is a frequent speaker and author on current topics in patent law.

Brinks Gilson & Lione is a sponsor of the third annual IP Strategy Summit: Seattle. The conference will explore effective strategies for an IP environment that is rapidly evolving in terms of patentable subject-matter, fee-shifting standards, and post-issuance proceedings. More information is at

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Brinks Gilson & Lione’s more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at